BiondVax universal flu vaccine patent application accepted in Australia
BiondVax Pharmaceuticals got its patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate accepted in Australia.
Pharmaceuticals, Biotechnology and Life Sciences
BiondVax Pharmaceuticals got its patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate accepted in Australia.
DUBLIN–(BUSINESS WIRE)–The “Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to…
HONG KONG–(BUSINESS WIRE)–Aptorum Group Ltd. (NASDAQ: APM), a preclinical stage pharmaceutical company developing and commercializing a broad portfolio of projects…
TRPC5 Inhibition with GFB-887 Protects Against Podocyte Injury and Proteinuria Associated with Focal Segmental Glomerulosclerosis and Treatment-resistant Minimal Change Disease…
The publication of the 2018 Annual Report marks the public debut ofNovocure’s newly defined vision, mission and values. Novocure launchedits vision, mission and values internally to its nearly 600 employees atthe end of 2018.
standalone implantation of two iStent®Trabecular Micro-Bypass Stents in newly diagnosed primary open-angleglaucoma (POAG) eyes achieved a 35.3% reduction in meanintraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.
The primary endpoint is the percent reduction in urinary oxalate frombaseline to six months. The Company expects to report initialILLUMINATE-B results in mid-2020.
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that it has expanded its existing…
DUBLIN–(BUSINESS WIRE)–The “US Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025” report has been added to ResearchAndMarkets.com’s offering. “US…